Kiniksa Q1 ARCALYST revenue $78.9M (+85% YoY); raises 2024 guidance to $370-390M

Kiniksa Pharmaceuticals International, plc

2024-Q1 EPS reported -$0.25 revenue$79,858,000

ARCALYST net product revenue $78.9M in Q1 2024, up 85% YoY; total revenue $79.9M vs $48.3M in Q1 2023.
Net loss $17.7M vs $12.3M loss in Q1 2023; cash and investments $213.6M, no debt outstanding.
Raises 2024 ARCALYST net product revenue guidance to $370-390M from prior $360-380M.
Plans to initiate abiprubart Phase 2b trial in Sjögren's Disease in second half of 2024.
About 2,000 prescribers have written ARCALYST since launch; average therapy duration ~23 months.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Kiniksa Pharmaceuticals International, plc reported first quarter 2024 results: revenue Total revenue for the first quarter of 2024 was $79.9 million, compared to $48.3 million for the first quarter of 2023., net income Net loss for the first quarter of 2024 was $17.7 million, compared to a net loss of $12.3 million for the first quarter. Guidance raised.

Period: first quarter 2024
Revenue: Total revenue for the first quarter of 2024 was $79.9 million, compared to $48.3 million for the first quarter of 2023.
Net income: Net loss for the first quarter of 2024 was $17.7 million, compared to a net loss of $12.3 million for the first quarter
Guidance: raised
Result: reported results

Exact text from the filing

On April 23, 2024, Kiniksa Pharmaceuticals, Ltd. issued a press release announcing financial results for the quarter ended March 31, 2024.

View on SEC.gov

1447 earnings releases filed in the last 30 days. Browse all earnings releases →

Kiniksa Pharmaceuticals International, plc filing history →

Source: SEC EDGAR

accession 0001104659-24-050335

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.